Cargando…

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a dismal prognosis. The cytoplasmic spleen tyrosine kinase (SYK) is highly expressed by hematopoietic cells and has emerged as a potential therapeutic target. In this study, we evaluated the in vitro antileukemic effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brattås, Marte Karen, Hemsing, Anette Lodvir, Rye, Kristin Paulsen, Hatfield, Kimberley Joanne, Reikvam, Håkon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737311/ https://www.ncbi.nlm.nih.gov/pubmed/36499034 http://dx.doi.org/10.3390/ijms232314706

Ejemplares similares

NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition
por: Hemsing, Anette Lodvir, et al.
Publicado: (2022)

PB1789: RAC1 INHIBITION IS FEASIBLE AND AFFECTS CELL MIGRATION IN A ZEBRAFISH LARVAE MODEL OF AML, INVESTIGATED USING A SOFTWARE TOOL FOR SINGLE-CELL VISUALIZATION
por: Hemsing, Anette Lodvir, et al.
Publicado: (2023)

Mondor’s disease after extensive training with Nordic walking
por: Hemsing, Anette Lodvir, et al.
Publicado: (2019)

Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment
por: Hansen, Bent-Are, et al.
Publicado: (2019)

Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review
por: Wiese-Hansen, Hanne, et al.
Publicado: (2021)

CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors
por: Brenner, Annette K., et al.
Publicado: (2017)

MicroRNA serum profiles and chronic graft-versus-host disease
por: Reikvam, Håkon, et al.
Publicado: (2022)

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2020)

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation
por: Hemsing, Anette Lodvir, et al.
Publicado: (2021)

Severe nephritis as initial sign of Waldenström’s macroglobulinemia
por: Knoop, Thomas, et al.
Publicado: (2019)

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
por: Nepstad, Ina, et al.
Publicado: (2019)

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
por: Nepstad, Ina, et al.
Publicado: (2018)

Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro Stress
por: Ryningen, Anita, et al.
Publicado: (2012)

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
por: Nepstad, Ina, et al.
Publicado: (2020)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2013)

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2021)

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism
por: Nepstad, Ina, et al.
Publicado: (2018)

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives
por: Reikvam, Håkon, et al.
Publicado: (2022)

Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity
por: Bartaula-Brevik, Sushma, et al.
Publicado: (2023)

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients
por: Hatfield, Kimberley Joanne, et al.
Publicado: (2022)

Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment
por: Vo, Anh Khoi, et al.
Publicado: (2020)

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation
por: Reikvam, Håkon, et al.
Publicado: (2015)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2023)

Clinical proteomics of myeloid leukemia
por: Hjelle, Sigrun M, et al.
Publicado: (2010)

Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation
por: Lindås, Roald, et al.
Publicado: (2014)

Future Perspectives: Therapeutic Targeting of Notch Signalling May Become a Strategy in Patients Receiving Stem Cell Transplantation for Hematologic Malignancies
por: Ersvaer, Elisabeth, et al.
Publicado: (2011)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2022)

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
por: Brenner, Annette K., et al.
Publicado: (2016)

Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells
por: Aasebø, Elise, et al.
Publicado: (2021)

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients
por: Johansen, Silje, et al.
Publicado: (2018)

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia
por: Johansen, Silje, et al.
Publicado: (2018)

Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome
por: Reikvam, Håkon, et al.
Publicado: (2015)

Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia
por: Boros, Katalin, et al.
Publicado: (2015)

SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism
por: Polak, Anna, et al.
Publicado: (2020)

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder
por: Bruserud, Øyvind, et al.
Publicado: (2020)

GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2
por: Lellahi, Seyed Mohammad, et al.
Publicado: (2023)

Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k77gsnbg8eaki26gee9hjc7o9f